MDT

98.85

+0.46%↑

A

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

A

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

A

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

A

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

A

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

Search

Embecta Corp

Open

SectorHealthcare

12.85

Overview

Share price change

24h

Current

Min

12.45

Max

12.85

Key metrics

By Trading Economics

Income

-19M

26M

Sales

-32M

264M

P/E

Sector Avg

7.883

90.831

Dividend yield

4.7

Profit margin

10

Employees

1,850

EBITDA

-40M

71M

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.70%

2.20%

Next Earnings

5 Feb 2026

Next Dividend date

13 Mar 2026

Next Ex Dividend date

27 Feb 2026

Market Stats

By TradingEconomics

Market Cap

-33M

761M

Previous open

12.85

Previous close

12.85

News Sentiment

By Acuity

50%

50%

151 / 361 Healthcare

Embecta Corp Chart

Past performance is not a reliable indicator of future results.

Related News

14 Jan 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 Jan 2026, 00:00 UTC

Earnings

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 Jan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 Jan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 Jan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 Jan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 Jan 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 Jan 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 Jan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 Jan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 Jan 2026, 22:09 UTC

Earnings

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 Jan 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 Jan 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 Jan 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 Jan 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 Jan 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 Jan 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 Jan 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 Jan 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 Jan 2026, 21:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

14 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Jan 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 Jan 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 Jan 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 Jan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 Jan 2026, 20:30 UTC

Market Talk
Earnings

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 Jan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 Jan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 Jan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 Jan 2026, 19:06 UTC

Market Talk
Earnings

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Comparison

Price change

Embecta Corp Forecast

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Sentiment

By Acuity

151 / 361 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat